インデックス付き
  • 学術雑誌データベース
  • Jゲートを開く
  • Genamics JournalSeek
  • ジャーナル目次
  • 中国国家知識基盤 (CNKI)
  • シマゴ
  • ウルリッヒの定期刊行物ディレクトリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • パブロン
  • ミアル
  • 大学補助金委員会
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • Google スカラー
このページをシェアする

概要

Nanocapsulated Rift Valley Fever Vaccine Candidates and Relative Immunological and Histopathological Reactivity in Out Bred Swiss Mice

Noha Emad El-Din Abd el-Razek, Sahar A. Shoman and Aly Fahmy Mohamed

The present work aimed to compare the potentials of Alum and CAP as adjuvants and related immune response to RVFV vaccines candidates inactivated using different inactivants namely, Formalin, Beta-Propiolactone (BPL) and Ascorbic acid (AA). Potency (ED50) of inactivated vaccines was arranged in the order of BPL (0.006), AA (0.0024), and formalin (0.011) respectively. Data recorded revealed that BPL inactivated showed a fast inactivating efficacy and inactivation time was arranged as BPL (2 hrs) followed by formalin (6 hrs) and AA (within 24hrs). BPL - CAP adjuvanted RVFV vaccine showed a higher and long durative antibody level than that detected post immunization with the other RFVF vaccine formulations either alum or CAP adjuvanted vaccines. Limited histopathological changes detected post CAP adjuvanted vaccine compared with that detected post Alum adjuvanted one was detected.